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1. Introduction 
Chronic hepatitis C virus (HCV) infection is the leading reason for liver transplantation in both 
the USA and Europe. Also, with increasing numbers of adult recipients, HCV associated liver 
disease is now becoming the leading indication for liver transplantation in Japan as well. The 
recurrence of HCV infection in the grafted liver is inevitable and HCV re-infection precedes 
acute hepatitis, which is usually detected between 1 and 3 months post-transplantation. Acute 
HCV is characterized by a rising serum alanine transaminase level and sometimes by a 
moderate elevation in bilirubin levels, resulting in varying degrees of liver graft damage. 
Acute HCV usually evolves to chronic hepatitis, which impairs both the graft and patient 
survival because the progression to liver cirrhosis is faster after liver transplantation than in 
nontransplant patients. A biopsy of the transplanted graft is helpful in establishing a diagnosis 
of recurrent HCV, in aiding the decision to undertake antiviral treatment, and in assessing the 
treatment response. The biopsy is assessed for grade (degree of necro-inflammation) and stage 
(extent of fibrosis) which help predict the likelihood of disease progression. 
There are still several problems with the diagnosis and treatment of recurrent HCV after liver 
transplantations. Especially during the first 6 months following transplantation, recurrent 
HCV infection frequently causes severe liver graft dysfunction. Also during this period, 
recurrent HCV is sometimes difficult to differentiate from other complications such as acute 
cellular rejection (ACR) and biliary complications because the histopathological changes of a 
grafted liver with recurrent HCV infection are often atypical. Thus, a definite histopathological 
diagnosis of recurrent HCV sometimes cannot be made solely based on the findings of 
hematoxylin-eosin (H&E) stained liver biopsies. The diagnosis of recurrent HCV and the 
decision to launch antiviral treatment is often difficult and stressful for clinicians.  
The detection of HCV replicative intermediates or antigens in liver biopsies may be helpful 
in the diagnosis and medical management of patients with recurrent HCV. In the following 
section, previous reports about the immunohistochemical detection of HCV antigens in liver 
grafts are reviewed and our data about immunohistochemical staining using IG222 
monoclonal antibody (mAb) against the HCV-envelope 2 (E2) protein are described. 
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2. Immunohistochemical analysis of liver grafts for recurrent HCV after liver 
transplantation 
2.1 Immunohistochemical detection of HCV antigens in patients with chronic HCV 
infection 
The identification of HCV antigens in the liver was first reported in 1990 (Krawczynski et al., 
1990). Several antibodies have been induced for the detection of HCV in liver biopsies. HCV 
antigens were detected exclusively in the cytoplasm of hepatocytes in specimens obtained 
from the livers of patients with chronic HCV infection, with a detection rate of 23-100% 
(Roskams, 2002; Scheuer et al., 1997). According to these reports, the number of positive 
hepatocytes and the intensity of staining were relatively low in most of the liver specimens. 
Clinically, the indication and management of antiviral therapy for HCV infection is decided 
according to liver biochemical tests, HCV genotype, and serum HCV-RNA levels. Thus, 
histopathological findings from liver biopsy are not necessarily essential for managing 
patients with chronic HCV infection. In addition, the histopathological features of chronic 
HCV infection are typical and are easily assessed for the disease diagnosis and progression 
from H&E stained liver biopsy specimens. Therefore, immunohistochemical detection of 
HCV antigens doesn’t necessarily seem to be valuable for the medical management of 
patients with chronic HCV infection. 
2.2 Immunohistochemical detection of HCV antigens for liver transplantation 
2.2.1 Problems of diagnosing and managing recurrent HCV  
In recurrent HCV infection in grafted livers, histopathological changes often exhibit from 
acute lobular hepatitis to chronic hepatitis in the majority of patients after transplantation. 
The severity of these changes, including necro-inflammatory activity and fibrosis 
progression, may vary depending on each case and the time after transplantation. 
Especially during the first 6 months following transplantation, recurrent HCV infection 
may cause severe liver graft dysfunction. During this period, the histopathological 
changes of a grafted liver with recurrent HCV infection are often atypical and difficult to 
differentiate from other complications, such as ACR and biliary complications. A definite 
histopathological diagnosis of recurrent HCV can be made when H&E stained liver 
biopsies show findings characteristic of recurrent HCV such as a variable degree of 
mononuclear portal inflammation, interface activity, lobular disarray, and spotty 
hepatocyte necrosis. However, in practice, the examination of H&E-stained liver biopsy is 
often done before a definite diagnosis of recurrent HCV hepatitis can be established. The 
clinical situations associated with the diagnosis and management of recurrent HCV are 
often stressful for clinicians.   
Antiviral treatment can be initiated in the early weeks after liver transplantation, 
irrespective of biochemically or histologically proven recurrent HCV hepatitis. However, 
according to preliminary studies, the response rate is not higher than in treatment 
initiated after a definite diagnosis and the tolerability of treatment in these early 
transplant periods is limited. This pre-emptive antiviral therapy soon after liver 
transplantation is still under evaluation. At present, antiviral treatment after a definite 
diagnosis of recurrent HCV is accepted as a standard therapy. Since early recurrent HCV 
often causes severe liver graft dysfunction, an early definite histopathological diagnosis is 
essential for the early commencement of antiviral therapy. Therefore, the detection of 
HCV replicative intermediates or antigens in liver biopsies may be helpful for the early 
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diagnosis and optimal medical management of patients with recurrent HCV after liver 
transplantation. 
2.2.2 Immunohistochemical detection of HCV antigens for recurrent HCV after liver 
transplantation  
The post-transplant HCV-RNA serum levels usually reach 10-20 times the pre-transplantation 
levels, presumably because of immunosuppression. Although it is easy to show systemic HCV 
infection through serum HCV-RNA levels, it is more difficult to evaluate the actual state of 
HCV infection in the grafted liver. The presence of HCV-RNA in liver biopsy specimens has 
been shown by in situ hybridization (Agnello et al., 1998) or by reverse-transcriptase in situ 
polymerase chain reaction (Fragulidis et al., 1998). However, these methods have technical 
difficulties and have not been widely used. In contrast, the detection of HCV antigens in liver 
grafts is easy and sensitive enough for clinical use in the management of patients after liver 
transplantation. Thus, considering the above-mentioned problems of diagnosing recurrent 
HCV, immunohistochemical detection of HCV antigens in liver grafts could provide 
potentially important pathological information, making possible a correlation between viral 
replication in liver grafts and recurrent HCV after liver transplantation. Several studies 
suggested that the immunohistochemical staining of HCV antigens in liver grafts correlated 
with the severity of recurrent HCV after liver transplantation (Gane et al., 1996; Pessoa et al., 
2008; Vargas et al., 1998; Verslype et al., 2003).  
2.3 Immunohistochemical staining of liver grafts using IG222 mAb against HCV-
Envelope 2  
Several monoclonal and polyclonal antibodies against HCV antigens have been used for the 
immunohistochemical analysis of HCV antigens in liver biopsy specimens of hepatitis C 
patients. Of these antibodies, IG222 is reported to have a strong immunoreactivity to the 
HCV-E2 protein in both fresh-frozen tissue and paraffin-embedded tissue (Verslype et al., 
2003). Verslype et al. reported that immunohistochemical staining using IG222 mAb had a 
sensitivity of 96%, a specificity of 91% and an overall accuracy of 94.8% in their 253 patients 
with chronic hepatitis C. Based on those findings, we decided to use IG222 for the 
immunohistochemical analysis of liver grafts. In this section, we describe our data 
(Sadamori et al., 2009) about the immunohistochemical staining of liver grafts using IG222 
mAb in patients who underwent liver transplantation for HCV associated liver failure. 
2.3.1 Longitudinal immunohistochemical analysis of a case of recurrent HCV 
Figure 1 summarizes the clinical course of a patient with early recurrent HCV after living 
donor liver transplantation (LDLT). Immunoreactivity to IG222 mAb was weakly positive 
on a liver biopsy specimen on postoperative day (POD) 31 showing moderate ACR (Fig. 2A 
and 3A). After the improvement of liver function tests by steroid pulse therapy, the liver 
function tests increased again around POD 55. A H&E stained liver biopsy on POD 59 
showed mild portal inflammation, endothelial inflammation of portal venules, and an intra-
acinar acidophilic body, leading to the diagnosis of probable recurrent HCV (Fig. 2B). At 
that stage, the immunoreactivity to IG222 mAb was already moderate (Fig. 3B). With further 
deterioration shown in liver function tests, another liver biopsy on POD 80 confirmed a 
definite diagnosis of recurrent HCV (Fig. 2C) accompanied by marked immunoreactivity to 
IG222 mAb (Fig. 3C). The findings in this case show the diagnostic usefulness of the 
immunohistochemical staining of liver grafts using IG222 mAb.   
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Fig. 1. Clinical course of a representative patient with post-LDLT early recurrent HCV. 
 
   
 
 
Fig. 2. Findings of H&E stained liver biopsy specimens (A) Liver biopsy specimen obtained 
on POD 31 showed moderate acute cellular rejection. (Original magnification x160) (B) Liver 
biopsy specimen obtained on POD 59 showed mild portal inflammation and an intra-acinar 
acidophilic body, leading to the diagnosis of probable recurrent HCV. (Original 
magnification x160) (C) Liver biopsy specimen obtained on POD 80 showed marked portal 
inflammation, intra-acinar inflammatory cell infiltration and intra-acinar spotty necrosis, 
leading to the diagnosis of definite recurrent HCV. (Original magnification x160) 
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Fig. 3. Immunohistochemistry for HCV-E2 in liver biopsy specimens   
(A) Immunohistochemistry for HCV-E2 in a liver biopsy obtained on POD 41 based on a 
suspected acute rejection episode. Note the weakly positive immunoreactivity to IG222. 
(Original magnification x200) (B) Immunohistochemistry for HCV-E2 in liver biopsy 
obtained on POD 59 of a case with probable diagnosis of recurrent HCV based on the 
examination of H&E-stained sections. Note the moderate immunoreactivity to IG222. 
(Original magnification x200) (C) Immunohistochemistry for HCV-E2 in a liver biopsy 
obtained on POD 80, of a case with definite diagnosis of recurrent HCV based on the 
examination of H&E-stained sections. Note the marked immunoreactivity to IG222. 
(Original magnification x200). 
2.3.2 Serial changes in immunoreactivity to IG222 mAb after LDLT 
Previous study reported that HCV antigen expression in transplanted liver grafts was 
detected as early as 10 days post-transplantation in 25% of liver biopsy specimens and 
within 3 weeks in 50% of specimens (Ballardini et al., 2002). By the time histological 
recurrent HCV is clinically overt, HCV antigens can be detected in more than 90% of liver 
biopsy specimens (Ballardini et al., 2002; Gane et al., 1996; Guerrero et al., 2000). We 
performed immunohistochemical staining using IG222 mAb on 84 liver biopsy specimens 
obtained from 28 patients who underwent LDLT for HCV associated liver failure. 
Immunohistochemistry using IG222 mAb was performed on paraffin sections of all liver 
biopsies by a two-step indirect EnVision technique. To investigate serial changes of HCV 
antigen expression in liver grafts, the 84 liver biopsy specimens were divided into three 
groups according to the time elapsed from LDLT: Group POD1-30 (28 specimens), Group 
POD31-179 (34 specimens), and Group POD≥180. (22 specimens). Table 1 lists the grade of 
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immunoreactivity to IG222 mAb in the above-mentioned three groups classified according 
to the time after LDLT. Immunoreactivity to IG222 for HCV-E2 was detected in 78.6% of the 
liver biopsy specimens obtained during the first month after LDLT, and there were no 
significant differences in the grades of immunohistochemical staining between the three 
groups classified according to the time elapsed from LDLT. Our data shows that constant 
HCV antigen expression in liver grafts is observed relatively early after liver transplantation 
and is not associated with the time elapsed from the transplantation. 
 
 
Table 1. The grades of IHS and serum HCV-RNA levels among three groups classified 
according to the time after LDLT   
2.3.3 Immunohistochemical staining with IG222 mAb for differentiating recurrent HCV 
from other complications 
Based on our histological evaluation of H&E stained specimens, 34 liver biopsy specimens 
obtained from LDLT recipients were diagnosed as follows: definite recurrent HCV in 12, 
probable recurrent HCV in 7, definite ACR in 7 and other complications in 8. The other 
complications comprised of drug-induced liver injury in 1, cytomegalovirus hepatitis in 1, 
cholestasis due to biliary stricture in 3 and non-specific cholestasis in 3. Figure 4 shows the 
grade of immunohistochemical staining with IG222 mAb in the above-mentioned four 
different post-transplant conditions. In our study, the grade of HCV-E2 expression was 
significantly higher in liver grafts with definite and probable recurrent HCV compared with 
those with ACR and other complications (mainly biliary complications). These data 
suggested that strong HCV-E2 expression in liver grafts is associated with recurrent HCV 
after LDLT when IG222 mAb is used for the immunohistochemical staining of the liver 
grafts. Therefore, immunohistochemical staining of liver grafts using IG222 mAb can be an 
innovative approach for differentiating recurrent HCV from other complications including 
ACR and for aiding the decision to commence antiviral treatment. 
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Fig. 4. IG222 immunohistochemical grading in four different post-transplant conditions. 
2.3.4 Correlation between immunohistochemical grading and serum HCV-RNA levels 
Previous reports investigated the relationship between serum HCV-RNA levels and 
recurrent HCV after liver transplantation. Some of these studies showed a close correlation 
between serum HCV-RNA levels and the presence and severity of recurrent HCV (Di 
Martino et al., 1997; Feray et al., 1994; Gottschlich et al., 2001). However, others groups  
 
 
Table 2. The grades of IHS and serum HCV-RNA levels in four different post-transplant 
conditions. 
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found no such correlation (Chazouilleres et al., 1994; Freeman et al., 1996; Zhou et al., 1996). 
In our study, the serum HCV-RNA levels in the specimens with definite and probable 
recurrent HCV were comparable with those with definite ACR and other complications 
(Table 2). In addition, the expression of HCV-E2 in liver grafts did not correlate with serum 
HCV-RNA levels when our data of 84 liver biopsy specimens was analyzed. Previous 
studies indicated that HCV can replicate efficiently in extrahepatic tissues and cell types, 
including peripheral blood mononuclear cells, lymph nodes, and bone marrow, particularly 
in immunosuppressed patients (Blackard et al., 2006; Laskus et al., 1998; Radkowski et al., 
1998). Extrahepatic replication of HCV may help explain the lack of correlation between 
serum HCV-RNA levels and HCV-E2 staining in liver grafts. 
2.3.5 Assessment of antiviral treatment response after liver transplantation 
The course of HCV recurrence after liver transplantation progresses more rapidly and more 
aggressively than in the immunocompetent non-transplant HCV-infected population. Chronic 
HCV is observed in almost 70 % of patients 3 years after transplantation (Feray et al., 1994). 
Moreover, as the progression rate of fibrosis is faster after transplantation, the rate of cirrhosis 
reaches about 20% at 5 years (Berenguer et al., 2000; Gane et al., 1996). Several attempts have 
been made to prevent a poor prognosis due to HCV recurrence. Antiviral therapy for patients 
on the waiting list is attractive, but many patients do not meet the inclusion criteria and cannot 
receive antiviral treatment. Even if antiviral treatment is initiated despite poor hepatic reserve, 
many patients will withdraw due to frequent serious adverse events.  
 
 
Fig. 5. Clinical course and immunohistochemical staining of liver grafts using IG222 mAb of 
a patient with recurrent HCV, who achieved sustained virological response (SVR) by 
antiviral therapy. 
Antiviral therapy after transplantation can contribute to the improvement of HCV disease 
progression in a minority of the overall HCV liver transplant population. In studies using 
combination therapy with interferon (IFN)-alpha and ribavirin or, more recently, pegylated 
interferon-alpha (PEG-IFN) plus ribavirin, a sustained virological response (SVR) was 
achieved in 20-30% of patients (Carrion et al., 2007; Samuel et al., 2003). Figure 5 shows the 
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clinical course and immunohistochemical staining of liver grafts using IG222 mAb of a 
patient with recurrent HCV, who achieved SVR by antiviral therapy. The grade of HCV-E2 
expression on the liver grafts decreased according to the continuation of antiviral therapy 
and became almost negative when SVR was achieved. 
At present, there is no effective therapy for those that don’t respond to antiviral therapy or 
patients who experience a viral relapse after antiviral therapy. For those patients, new 
innovative strategies to improve therapeutic efficacy and tolerability are needed for the 
medical management of recurrent HCV after liver transplantation. In addition, 
immunohistochemical staining of liver grafts with IG222 mAb, directed against HCV-E2, 
may be useful for the actual evaluation of new medical treatment responses especially for 
those that don’t respond to antiviral therapy.  
3. Conclusion 
Through the immunohistochemical staining of HCV antigens using reliable antibodies we can 
assess the actual HCV re-infection and replication in transplanted liver grafts. According to 
previous studies and our data, the immunohistochemical staining of HCV antigens on liver 
grafts can contribute to the early and prompt diagnosis of recurrent HCV after liver 
transplantation. Based on our study, immunohistochemical staining of liver grafts using IG222 
mAb is sensitive enough for clinical use and can be useful for differentiating recurrent HCV 
from other complications, including ACR, and for aiding in the decision to commence antiviral 
treatment. In the future, the immunohistochemical staining of HCV antigens on liver grafts 
should be able to contribute toward identifying patients suitable for early antiviral therapy 
and assessing the antiviral treatment response for recurrent HCV after liver transplantation. 
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